Longevity & AgingHypereosinophilia in 2025: New Classification Systems and Expanding Biologic Therapies
Hypereosinophilia (HE) and hypereosinophilic syndrome (HES) are complex disorders involving pathologically elevated eosinophils capable of damaging multiple organs including the heart, lungs, skin, and nervous system. This 2025 review consolidates updated classification frameworks from both the Valent group and the Italian SIAAIC task force, distinguishing hereditary, reactive, neoplastic, and idiopathic subtypes. Corticosteroids remain first-line therapy, while imatinib shows high efficacy in FIP1L1::PDGFRA-positive patients. Anti-IL-5 biologics mepolizumab and benralizumab demonstrate meaningful eosinophil reduction and flare prevention. Investigational agents including dupilumab and lirentelimab are expanding the treatment horizon. Accurate classification is critical for organ-damage prevention and quality-of-life improvement.
